News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Visient Therapeutics, Inc. Treats First Patient In Phase 1 Trial Of Litx(TM) For Advanced Age-Related Macular Degeneration



10/19/2005 5:12:50 PM

SEATTLE, Feb. 24 /PRNewswire/ -- Visient Therapeutics announced today that it has enrolled the first patient in a newly commenced Phase 1 clinical trial evaluating Litx in patients with advanced age-related macular degeneration. Ophthalmologist Gary Edd Fish, M.D., treated the patient at Texas Retina Associates in Dallas.

The Food & Drug Administration (FDA) accepted an Investigational New Drug (IND) application in 2004. This permitted Visient Therapeutics to begin an open-label, dose escalation safety trial using the light-activated drug LS11 (talaporfin sodium) to treat patients with advanced age-related macular degeneration (AMD). In this study, LS11 will be administered to patients intravenously, and then activated selectively in diseased portions of the eye by light.

"Beginning our ophthalmic clinical trials for AMD is a significant accomplishment for Visient," said Albert Luderer, Ph.D., President of Visient Therapeutics and President and CEO of parent company, Light Sciences. "The quick acceptance of our IND by the FDA really underscores the safety profile that we have seen with this compound. We believe that our unique approach may solve many of the major problems associated with currently available therapies, such as poor response rates, inadequate durability of visual stabilization and uncomfortable drug delivery mechanisms."

AMD is the leading cause of irreversible blindness for those aged 55 and over. Nearly 200,000 people are diagnosed with AMD in the United States every year.

About Visient Therapeutics

Visient Therapeutics is wholly owned subsidiary of Light Sciences Corporation. Light Sciences Corporation, founded in 1995, is a privately owned company developing Light Infusion Technology (Litx), a proprietary combination product comprising a photo-reactive agent (LS11) activated by non-coherent light infusion devices. Litx represents an important step forward in the clinical application of light activated drugs in cancer, cardiovascular, eye and many other diseases. For additional information about Light Sciences, please visit http://www.lightsciences.com/ .

NOTE: Light Sciences(R), Litx(TM) and Light Infusion Technology(TM) are registered or proprietary marks of Light Sciences Corporation.

Contact: Al Luderer President and CEO Visient Therapeutics 425-369-2800 info@lightsci.com Kristie Kuhl Makovsky & Co. 212-508-9642 kkuhl@makovsky.com

Visient Therapeutics

CONTACT: Al Luderer, President and CEO of Visient Therapeutics,+1-425-369-2800, or info@lightsci.com; or Kristie Kuhl of Makovsky & Co.,+1-212-508-9642, or kkuhl@makovsky.com, for Visient Therapeutics


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES